Obsidian’s lead programs incorporate controllable functions into CAR-T and other cellular medicines so they can be precisely tuned by a companion small-molecule medicine to control and optimize therapeutic effect.

Obsidian is using DD technology to create a suite of regulated factors that can be incorporated into cell and gene therapies to provide pharmacological control of enhanced therapies for cancer and other diseases.

Based upon the work of professor Thomas Wandless, a researcher in chemical and systems biology, Obsidian was founded in 2015 and is funded by a syndicate of venture investors.

The company is headquartered in Cambridge, Massachusetts.